August 20122012:::: Financial Highlights of the Life Sciences Industry Biotech Therapeutic Financing Rounds

WeWelcomelcome to Venture Valuation’s VC Financial Summary

July saw a resurrection in both the number of biotech therapeutic and diagnostic venture capital rounds, and the amount of total funding. After a sluggish first half to the year, the biotech industry shared a sigh of relief as nearly USD 600 M in new financing flowed to biotech companies last month. Of particular importance is the resurgence of the European and Rest of World financing which has been characterized by low total number of rounds as well as smaller average financing per round. While the US had weathered the sluggish biotech investing landscape well, the dramatic increase in total rounds over the last 2 months is also an encouraging sign.

August 20122012:::: Financial highlights of the life sciences industry Biotech Therapeutic Financing Rounds

40 700

35 600

30 500

25 400 20 300 15

200 10 TotalTotal Value Value in in MillionMillion USD USD TotalTotal Value Value in in MillionMillion USD USD 5 100 TotalTotal Number Number ofof Financing Financing RoundsRounds TotalTotal Number Number ofof Financing Financing RoundsRounds 0 0

Jul 11 Aug 11 Sep 11 Okt 11 Nov 11 Dez 11 Jan 12 Feb 12 Mrz 12 Apr 12 Mai 12 Jun 12 Jul 12 Financing Value EU 41 27 106 55 200 70 138 24 69 32 24 28 111 Financing Value US 205 150 202 379 466 172 177 219 502 308 239 285 436 Total Rounds EU 6 6 10 9 101013 6 7 5 5 6 7 Total Rounds US 12 13 11 17 17 18 13 14 20 20 19 26 34 *The graph contains only financing rounds of private and independant biotech Therapetuic and Diagnostic companies

Financing rounds

Nabi Biopharmaceuticals Announces Commencement of Selfelf----TenderTender Offer for Up To USD 23 M of Its Common Stock

Nabi Biopharmaceuticals (Rockville, MD. USA) announced that it is commencing a "modified Dutch auction" tender offer for up to USD 23 M of its common stock at a price per share not less than USD 1.58 and not greater than USD 1.72. The tender offer expired at 12:00 midnight, at the end of the day, New York City time, on Monday, July 30, 2012. Tenders of shares had to be made on or prior to the expiration of the tender offer and withdrawn at any time prior to the expiration of the tender offer, in each case, in accordance with the procedures described in the tender offer materials.

A "modified Dutch auction" tender offer allows stockholders to indicate how many shares and at what price within the Company's specified range they wish to tender. Based on the number of shares tendered and the prices specified by the tendering stockholders, the Company will determine the lowest price per share within the range that will enable the Company to purchase USD 23 M of its common stock.

The Company expects to fund the share purchases in the tender offer using available cash on hand. The tender offer will not be conditioned upon any minimum number of shares being tendered, but will be subject to a number of conditions that are described in the tender offer materials.

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction. Nabi Biopharmaceuticals is currently developing NicVAX (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. (Source: Company website)

MDxHealth Successfully Raises EUR 10 M In Equity Offering

MDxHealth SA (Liege, Belgium), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, announced that it has successfully raised EUR 10 M in gross proceeds through a private placement of new shares with investors in various jurisdictions. Pursuant to the private placement, MDxHealth will issue 1,996,008 new ordinary shares to Biovest Comm. VA. at an offer price of EUR 1.503 and 4,895,105 new ordinary shares to a range of other investors at an offer price of EUR 1.430.

The payment and delivery of the new shares took place on July 4, 2012, at which time the new shares were admitted to listing, subject to the approval and publication of a listing prospectus. The new shares were fully interchangeable with the existing shares on NYSE Euronext. Immediately after the closing of the private placement, MDxHealth’s issued and outstanding shares will increase by 27% from 18,622,327 to 25,513,440 ordinary shares.

MDxHealth is a leading molecular diagnostics company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation

technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy....(Source: Company website)

Palatin Technologies, Inc. Announces Pricing of USD 35 M Private Placement of Common Stock and Warrants

Palatin Technologies, Inc. (Cranbury, NJ. USA) announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shares of its common stock, and Series B warrants to purchase 35,488,380 shares of its common stock. Funds under the management of QVT Financial LP have agreed to pay USD 0.50 for each share of common stock and USD 0.49 for each Series A warrant and each Series B warrant, resulting in gross proceeds to Palatin of USD 35 M, with net proceeds, after deducting estimated offering expenses, of approximately USD 34 M.

Palatin intends to use the proceeds from this offering for general corporate purposes and working capital, including its clinical trial program with bremelanotide for female sexual dysfunction, preclinical and clinical development of its melanocortin receptor-1 peptide program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.

Both Series A and Series B warrants are exercisable at an initial exercise price of USD 0.01 per share. The Series A warrants are exercisable immediately upon issuance and expire on the tenth anniversary of the date of issuance. The Series B warrants are also exercisable immediately upon issuance, but only if Palatin’s stockholders increase the number of its authorized shares of common stock, and expire on the tenth anniversary of the date of the increase in the number of authorized shares. Both the Series A warrants and the Series B warrants are subject to limitation on exercise if the holder and its affiliates would beneficially own more than 9.99% of the total number of Palatin’s shares of common stock following such exercise.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. (Source: Company website)

Genkyotex closes CHF 25 M extension to its Series C financing.

Genkyotex (Geneva, Switzerland),, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced the closing of a CHF 25 M (USD 26 M) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.

Proceeds from the round will be used to advance clinical development of Genkyotex’s lead compound, the NOX1/4 inhibitor GKT137831, through Ph II development for the treatment of diabetic nephropathy and to progress pipeline molecules targeting different diseases. Results from initial single-dose Ph Ia

studies suggest that GKT137831 is safe and well tolerated. The ongoing multi-dose Ph Ib study is expected to finish later this quarter.

Concurrent with the financing, Genkyotex has appointed Eric Meldrum, PhD, as Chief Scientific Officer. Eric joins Genkyotex with over 18 years of experience working in large pharmaceutical companies and biotech, specializing in discovery and preclinical drug development. In addition, Alexandre Grassin has joined Genkyotex as finance director. Alexandre previously held positions in finance with Novartis and Alexion.

Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. The Series C investment was led by Edmond de Rothschild Investment Partners and included Vesalius BioCapital and MP Healthcare Venture Management. (Source: Company website)

RDD Pharma Gains USD 7.15 M from Orbimed in First Round Financing

OrbiMed Israel has signed a definitive agreement to invest USD 7.15 M in RDD PHARMA (Ofakim, Israel), a company developing drugs for ano-rectal diseases. This is the first major round of financing for the company, which was founded in 2009 by Dr. Nir Barak and Mor Research Applications, the technology transfer company of Clalit Health Services. Currently, RDD PHARMA is operating under the auspices of the Ofakim incubator, owned by Capital Point. Dr. Nissim Darvish and Erez Chimovits from OrbiMed Israel will join the company's board.

The company is pursuing two indications: anal fissures and spinal-cord-injury-related-fecal- incontinence, both in the clinic.

Dr. Barak noted that aside from the vital funding, the partnership with OrbiMed also brings extensive knowledge and experience in drug development, and will allow the company to benefit from the fund's international team. (Source: Company website)

Psioxus Therapeutics Secures GBP 22 M in Series B FinancingFinancing to Drive Clinical Development For Oncolytic Vaccine

PsiOxus Therapeutics, Ltd. (Oxford, United Kingdom) announced that it has closed a Series B round of equity financing totaling GBP 22 M (USD 34 M). The round included equal investments from existing investors Imperial Innovations Group and Invesco Perpetual together with new investments by SR One and Lundbeckfond Ventures.

The financing round will enable PsiOxus to advance the clinical development of ColoAd1, a systemically available oncolytic vaccine, through a series of Ph I and Ph II clinical trials for the treatment of colorectal and other forms of cancer. PsiOxus was formed to commercialise technologies, generated

in leading UK Universities, which were originally seed funded by Imperial Innovations and the Mercia Fund. ColoAd1 is a unique therapeutic candidate developed using the evolutionary principle of natural selection to generate an oncolytic vaccine with optimal anticancer properties. The vaccine is injected into the bloodstream and can replicate in and kill cancer cells but not normal cells. Each infected cell produces thousands of new copies of ColoAd1, which then spread to nearby cancer cells and kills them as well. The approach thus represents a new generation of 'self-amplifying' cancer therapy that has both a direct tumor killing and cancer vaccine effect. The first clinical trial of ColoAd1 will be initiated later this year in patients with metastatic solid tumours, to determine the safety and tolerability of the vaccine.

PsiOxus Therapeutics is a development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. ColoAd1 is an oncolytic vaccine for the systemic treatment of metastatic cancer, which has demonstrated exceptional anti-cancer properties in late pre-clinical development and will begin clinical development later in 2012. MT-102 is a dual action Anabolic Catabolic Transforming Agent (ACTA) in Ph II clinical development for the treatment of cachexia and sarcopenia. The Company is also developing treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. (Source: Company website)

Cartilage Implant Company CartiHeal EEExpandsExpands FFFinancingFinancing to USD 10 M

Cartilage implant developer CartiHeal Ltd.(Tel Aviv, Israel) has expanded its financing round to USD 10 M from USD 5 M, after Elron Electronic Industries Ltd. joined Accelmed, the fund of Moshe Arkin and Uri Geiger, and Access Medical Ventures, a US fund run by Israelis Limor Sandach, Dvir Keren, and Michael Tal. CartiHeal is a graduate of Peregrine Ventures Incentive Technological Incubator.

CartiHeal CEO Nir Altschuler, a biomedical engineer, founded the company in 2009, on the basis of a concept discovered at Ben Gurion University of the Negev. The company's preclinical trial of its articular cartilage and osteochondral defect repair product, Agili-C, was successful, and enough for EU CE Mark certification.

The Agili-C is made of two parts. The first combines aragonite, and the other is made of aragonite and hyaluronic acid is biocompatible and biodegradable. It does not include living tissue, in contrast to most innovative products under development. Companies in the cartilage reconstruction segment estimate the market at USD 3 B a year, although most products are still only experimental. (Source: www.globes.co.il website)

MedicalMedical----DeviceDevice Maker Avinger Taps Individual Investors for USD 33 M Series D

Avinger Inc. (Redwood City, CA. USD), a privately held medical-device maker that has seen its valuation go north of USD 100 M without any funding or involvement from venture firms, has once again tapped its network of high-net worth individuals, raising a USD 33 M Series D round to further commercialise some products and move others through the regulatory process.

J.D. Simpson said the company's backers are successful business executives, most of them working in fields outside of the medical-device industry. He declined to name the investors, and declined to discuss the stakes that they hold in Avinger.

The company aims to have all of its clinical data on Ocelot submitted to the FDA in the coming months. (Source: company website)

Medical devicedevicess player Neuravi raises EUR 5.2 M in Series A finanfinancingcing

An investment worth EUR 5.2 M led by Fountain Healthcare Partners and Delta Partners in Neuravi Ltd (Galway , Ireland) will accelerate the medical device company’s development of a ground-breaking clot retrieval device for the treatment of acute ischemic strokes and will enable Neuravi to undertake clinical evaluation in patients.

Established in 2009, Neuravi has assembled a large body of intellectual property in the field of mechanical retrieval devices for stroke and has positioned itself to be a major strategic player in this fast-developing market.

People suffer an estimated 700,000 ischemic strokes in the US and a further 950,000 in Europe each year.

Neuravi is developing a medical device to help stroke doctors treat patients quickly after stroke onset by removing the lodged blood clot from the brain with its proprietary Stent Basket technology.

Some 95% of patients currently receive no acute intervention for this often deadly or debilitating condition, relying on rehabilitation only. The potential market could be as high as USD 2 B per year following successful clinical trial completion and the products being approved for sale in major markets. (Source: Siliconrepublic.com)

Scripps Research Institute Wins USD 77 M to Develop AIDS Vaccine Center

The Scripps Research Institute (La Jolla, CA. USD) has been awarded a grant expected to total more than USD 77 M from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The new seven-year project will focus on developing a vaccine against HIV and the disease it causes, AIDS.

The Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery (CHAVI-ID) will conduct multidisciplinary research into immune responses that prevent infection or control the virus in infected individuals. The team will also generate vaccine components to induce such immune responses and provide broad protection against HIV infection.

The CHAVI-ID award to Scripps Research was one of two in the nation. The other went to Duke University in Durham, NC.

The initial award provides USD 11.1 M for the first year of the Scripps Research-based center. (Source: Institutes website)

GLOBVAC Awards BiBionoronor Pharma USD 1.7 M to Advance ResearchResearch Towards aann HIV Cure Using Vaccine VaccVacc----4x4x4x4x

Bionor Pharma ASA (Oslo, Norway) announced that the Research Council of Norway, through its GLOBVAC program, has awarded Bionor USD 1.7 M to help fund a study that researchers hope will lead to a better understanding of how Vacc-4x can contribute to an eradication strategy for HIV. Bionor is the only company from Industrial Sector approved for funding.

The grant is titled "Towards Eradication of HIV-1: Therapeutic Vaccination with the peptide-based candidate Vacc-4x."

The award will help fund a multinational study to "reboost" patients from the previously conducted Ph IIb study with Vacc-4x. The aim of the new study is to see if additional vaccinations, over time, can further reduce viral load while patients are not on conventional HIV medicine.

ART is not a cure, and the treatment can cause serious side effects. ART does not kill virus producing cells, and it blocks virus production only while patients take the medication. ART must therefore be a daily, lifelong treatment. In contrast, Vacc-4x is developed to provide long lasting virus control by training immune cells to seek out and kill virus-producing cells, without any serious side effects.

In addition to the reboost study, the funding will also cover the cost of a smaller study of an adjuvant used together with Vacc-4x, required by FDA as part of Bionor's path to marketing clearance for Vacc- 4x. (Source: Yahoo Finance)

Upstart Sprout scores USD 20 M round to revive fallen female libido drug

From the ashes of Boehringer Ingelheim's female sexual dysfunction research, Sprout Pharmaceuticals (Raleigh, NC. USA) has risen and taken in capital from a USD 20 M round to give BI's female libido drug flibanserin another go with U.S. regulators. A flock of angel investors have decided to back the Raleigh, NC-based startup and its ambitious plan to seek another approval of the drug without doing additional clinical trials.

The risky gamble could pay off if the company succeeds in winning approval for a drug that can combat underactive libidos in women, as there's currently no FDA approved sexual dysfunction drugs for females as there are for males with products such as Pfizer's Viagra and Eli Lilly's Cialis. Those products have fueled a blockbuster market for erectile dysfunction drugs, and developers hope to score big with female answers to those treatments.

As Sprout commercial chief Cynthia Whitehead tells the publication, the startup believes that a retooled new drug application with existing data from Boehringer's studies should be enough for FDA approval. This gambit might surprise those who have followed the program. FDA advisers shot down the drug as treatment for women's underactive libidos in 2010, saying that additional data would be needed to support the efficacy and safety of the drug. U.S. regulators followed up its panel's rejection of the drug with a Complete Response to Boehringer, which decided to scrap development of the program.

To become the first company to win U.S. approval of a "female Viagra," Sprout will have to outpace BioSante Pharmaceuticals and Apricus Biosciences. (Source: FierceBiotech)

IntegraGen Announces Additional Financing

IntegraGen, (Cambridge, MA. USA) a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, announced that the company has received EUR 2 M in financing from funds managed by A Plus Finance. The amount raised reinforces investors’ confidence in IntegraGen’s efforts to develop and market advances in molecular diagnostics and the company’s financial performance in the field of genomic services. Building upon an existing strong cash position, these funds will sustain the development of genetic tests in colorectal and liver cancer as well as speed up R&D and commercialization efforts in the field of autism molecular diagnostics.

Founded in 2000, IntegraGen is a biotechnology company specialized in the research and identification of genetic biomarkers for the development and marketing of products and services for molecular diagnosis. The IntegraGen mission is to offer clinicians new personalized tools for diagnosis, treatment and therapy. IntegraGen and its American affiliate IntegraGen Inc. strive for the prevention and proactive management of complex, debilitating illnesses and disorders by delivering the best response to the needs of clinicians and their patients. The Business Genomic Services division at IntegraGen also provides cutting edge services in the genotyping domain for scientific research. With research and intellectual property focused on autism and oncology, IntegraGen’s strategy is to offer a range of products and services for molecular screening and diagnosis to optimize personalized healthcare for complex illnesses and conditions. (Source: Company website)

Juventas Therapeutics Raises USD 22.2 M Series B Financing

Juventas Therapeutics,(Cleveland, OH. USA) a clinical-stage regenerative medicine company, announced that it has closed a USD 22.2 M Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures. All previous venture firms, including Fletcher Spaght Ventures, Reservoir Venture Partners and Early Stage Partners participated in the round. Also joining

the syndicate are new investors Takeda Ventures, Venture Investors, Global Cardiovascular Innovation Center, Tri-State Growth Fund, Glengary and select angel investors.

The proceeds will fund completion of ongoing Ph II clinical trials investigating the use of JVS-100 in treating patients with chronic heart failure or critical limb ischemia. Both trials are actively enrolling patients. JVS-100, the Company's lead product, encodes Stromal cell-Derived Factor 1 which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevent ongoing cell death and restore blood flow.

Clinical studies by several companies have demonstrated that delivery of adult stem cells to patients suffering from heart failure or critical limb ischemia has the potential to promote tissue repair and improve clinical outcomes. In spite of these clinical findings, questions remain about the affordability and accessibility of cell-based therapy for the general population. Rather than deliver cells, Juventas delivers JVS-100, which activates natural stem cell based repair pathways that lie dormant in a patient. This allows the benefits of regenerative medicine without the complexity of cell therapy. While currently focused on cardiovascular disease, the clinical potential for JVS-100 is broad.

Last year, Juventas Therapeutics spun-off SironRX Therapeutics to focus on development of dermal and bone related applications for JVS-100. In 2011, SironRX raised USD 3.4 M through a Series A financing led by North Coast Angel Fund and received USD 1 M in grant funding through the Ohio Third Frontier program. The Company is currently enrolling a Ph Ib randomized, placebo-controlled, double- blinded clinical trial investigating dermal JVS-100 delivery to accelerate wound closure and reduce scar formation.(Source: Company website)

bbb-b---totototo----vv Partners AG invests in Curefab

The Swiss investment company b-to-v Partners AG, together with an investor group composed of several industry experts along with founding investors High-Tech Gründerfonds and Bayern Kapital, have taken over the continuing financing for the Munich-based company Curefab GmbH.(Munich, Germany) The medical technology company has developed a scanning enhancement for ultrasound devices which converts conventional 2D scans into high-resolution 3D volume-scans. Expensive and elaborate methods like MRI, or methods which are harmful to the patient like CT, are now no longer necessary for many clinical applications.

Curefab's image-processing system makes medical ultrasound diagnostics more objective, faster, and much easier to document. It can be attached to any ultrasound system on the market and offers for the first time user-independent and reproducible ultrasound diagnoses. Thirty-six different application areas have already been identified for the existing technology. At the moment the company is concentrating on the visualization and investigation of blood vessels for stroke-prevention, and on determining the stage of head and neck tumors.

With the funding raised Curefab plans to further optimize and clinically validate its technology for routine clinical practice, establish new applications, and continue to expand its distribution structure. (Source: Company website)

Coferon, Inc. Announces USD 12 M Series B Financing

Coferon Inc. (Stoney Brook, NY. USA), a privately held, New York-based biotechnology company, announced that it has closed on a USD 12 M Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD; and Ascent Biomedical Ventures of New York, N.Y.

Coincident with the financing, Dr. Colin Goddard, who had been acting as a part-time Executive Chairman for Coferon and was formerly Chief Executive Officer of OSI Pharmaceuticals, Inc. up until its USD 4 billion acquisition by Astellas Pharma Inc. in 2010, has agreed to assume the leadership of the Company as Chairman and Chief Executive Officer.

The financing comes after a technically successful early investor phase in which the Company has been able to demonstrate initial proof-of-concept for the Coferon approach, which uses the Company's proprietary bioorthogonal linker chemistry to deliver small molecules in component parts that are designed to self assemble on their target inside the cell creating therapeutic molecules with enhanced size, potency and selectivity. Coferon is applying the technology against an anti-infectives target and in a comprehensive program targeting intracellular epigenetic regulatory proteins and their Protein Interaction Domains (PIDs). The greater binding footprint conferred by coferon dimers can potentially yield much higher binding affinities and more selective modulation of the individual members of closely related families of epigenetic regulatory binding domains such as the BRD family. Therapeutics targeting the BRD family, most notably BRD4, are actively being pursued by many companies with classic small molecule approaches. The BRD4, BRD2, BRD-T and the BRD-NUT oncogenic fusion protein all offer intriguing targets for therapeutic intervention and are an initial focus of the Coferon epigenetic discovery program.

The Company also announced that it is in the process of establishing its headquarters and laboratory operations at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York. (Source: Marketwire.com)

Durata Therapeutics Closes Initial Public Offering

Durata Therapeutics (Morristown, NJ. USA) announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of USD 9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.

BofA Merrill Lynch and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences acted as the co-managers for the offering.

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Ph III clinical trials with its lead product candidate,

dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI. (Source: Company website)

PTC Therapeutics Closes USD 30 M Financing

PTC Therapeutics, Inc. (South Plainfield, NJ. USA) announced the completion of a USD 30 M financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors.

PTC recently announced results from a Ph III study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis. An extension study for patients previously enrolled in the trial is ongoing. An open-label trial for Duchenne and Becker muscular dystrophy patients who received ataluren in a prior, PTC-sponsored clinical study is also ongoing while PTC continues the dialogue with regulatory authorities regarding next steps in ataluren's development. In both Duchenne and Becker muscular dystrophy and cystic fibrosis, ataluren has demonstrated clinically meaningful trends in the primary endpoints and in supporting secondary endpoints. It was generally well tolerated; serious adverse events were infrequent and not considered to be related to the drug. PTC owns the worldwide rights for ataluren across all indications.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post- transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. Company website)

Cell Medica Secures GBP 17 M Equity Investment to Establish US Operations and Fund Cell Therapy Development

Cell Medica (London, United Kingdom), a leading cell therapeutics company, announced it has secured a GBP 17 M (USD 26.5 M) equity investment to launch new operations in Texas focusing on cancer immunotherapy and to continue development of its immune reconstitution cell therapies in Europe. The financing includes new investment from Invesco Perpetual and Imperial Innovations alongside a previously announced Commercialisation Award from the Cancer Prevention and Research Institute of Texas. Contemporaneous with the financing, the Wellcome Trust will become a shareholder in the Company through conversion of a loan security into equity.

The equity capital will finance a significant build-up of the Company’s operations in both the United States and Europe. As part of this strategy, existing director Dr. Thomas Hecht will assume the Chairman’s role while the current Chairman Nigel Burns will carry on as a non-executive Director. Dr.

Hecht brings significant experience to the role of Chairman through his involvement in other early stage biotech companies and his previous role as a senior executive in Amgen’s European Operations.

Cell Medica is a cell therapeutics company engaged in the development, manufacture, marketing and distribution of cell-based products for immune reconstitution and cancer. The Company’s Cytovir product family for immune reconstitution targets the prevention and treatment of infections caused by latent viruses in immuno suppressed patients following allogeneic haematopoietic stem cell transplant. In the field of cancer immunotherapy, Cell Medica is targeting a range of cancers associated with the oncogenic Epstein Barr Virus. (Source: Company website)

Chiasma Closes USD 38.5 M Equity Financing

Chiasma Inc. (Jerusalem, Israel), a privately held biopharma company, announced that it closed a USD 38.5 M equity financing co-led by new investor Abingworth and current investor MPM Capital that also included investments from existing shareholders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures and Fredric Price, Chiasma’s Chairman & CEO.

The new investment, a Series D round, is expected to provide funding for the completion of the Ph III pivotal program in acromegaly patients for Octreolin, the Company’s proprietary investigational oral form of the peptide octreotide, which is planned to be completed in the second quarter of 2013. It is also intended to finance a clinical study for the Company’s second product, a small molecule to be investigated as a possible treatment for a complication of chronic kidney disease.

The Food and Drug Administration has granted orphan drug designation for Octreolin for acromegaly. If an NDA is approved, Octreolin would qualify as an Orphan Drug and would benefit from seven years of market exclusivity, potential tax credits, and a waiver of the prescription drug user fee for the marketing application. The Company expects to submit an application for Octreolin for acromegaly for Orphan Medicinal Product Designation to the EMA in 2013.

Chiasma is developing oral drugs that previously were only available by injection, thereby providing patients with pain-free medications that are self-administered. The Company’s lead candidate is an oral form of the peptide octreotide, initially being developed for patients with acromegaly that is in a Ph III trial with results expected in the second quarter of 2013. The Company is also developing an oral small molecule intended to replace a drug that is currently available by intravenous injection to treat a complication of chronic kidney disease; it is planned to enter the clinic in the third quarter of 2012. Chiasma is evaluating additional proteins, peptides and small molecules that can be applied to its proprietary Transient Permeability Enhancer technology to enable oral delivery of drugs that previously were available by injection only. Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary. It is backed by Abingworth, MPM Capital, 7 Med Health Ventures, ARCH Venture Partners, and F2 and F3 Ventures.(Source: Company website)

Proceeds to Drive Completion of Ph IIIIII NeoCart Clinical Trials and EU Regulatory Clearance of VeriCart

Regenerative medicine company Histogenics Corporation, (Waltman, MA. USA) announced the completion of a USD 49 M round of financing. The syndicate was led by Sofinnova Ventures with participation from additional new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. Existing investors ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also participated in the financing. Proceeds will be used to complete the ongoing Ph III clinical program for lead product candidate NeoCart, which is currently enrolling patients. NeoCart is an autologous neocartilage tissue implant that utilizes the patient’s own cells to regenerate cartilage in patients suffering from cartilage lesions in the knee. Funds will also support efforts to obtain regulatory clearance in the European Union for product candidate VeriCart, a single-step, cell-free collagen scaffold uniquely designed to be used in conjunction with the patient’s own stem cells, to repair small cartilage defects frequently observed in meniscal and anterior cruciate ligament repair procedures. Garheng Kong, MD, PhD of Sofinnova Ventures and Josh Baltzell of Split Rock Venture Partners will join Histogenics’ Board of Directors. Arnold Freedman of Boston Equity Advisors served as the exclusive placement agent. (Source: Company website)

Bluebird Bio Secures USD 60 M in Oversubscribed Financing bluebird bio, (Cambridge, MA. USA) a leader in the development of innovative gene therapies for severe genetic disorders, announced the successful completion of a USD 60 M Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.

Proceeds will be used to advance the company’s clinical programs in severe genetic disorders, including childhood cerebral adrenoleukodystrophy, beta-thalassemia and sickle cell disease. With the proceeds from this financing and based on promising early clinical proof of concept results, bluebird bio plans to initiate a Ph II/III clinical study in CCALD in both the United States and Europe in 2013, as well as a second U.S.-based Phase I/II study in betathalassemia in 2013. In addition, the company expects to initiate a more extensive sickle cell disease development program and invest in manufacturing, clinical and commercial infrastructure to support the upcoming clinical trials and pre- commercial launch activities. bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s own bone marrow into which a healthy version of the disease causing gene is inserted. bluebird bio’s approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy using a patient’s own stem cells. bluebird bio has two later stage clinical products in development for childhood cerebral

adrenoleukodystrophy and betathalassemia, and plans to initiate a program in sickle cell disease. (Source: Company website)

Coda Therapeutics gets USD 20 M

CoDa Therapeutics, Inc. (San Diego, CA. USA) has raised USD 20 M from RusnanoMedInvest. The funding represents a second close of its Series B financing, the company said, bringing the total in the round to nearly USD 40 M.

The investment is the first under an agreement between Rusnano, the parent company of RusnanoMedInvest, and Domain Associates, reached in March 2012. All current investors, including Domain Associates, GBS Ventures and BioPacificVentures participated.

CoDa is developing wound healing drugs. Some of the money raised will be used to expand late stage clinical trials of Nexagon, the company's lead product candidate, for additional uses, including diabetic foot ulcers. (Source: www.nctimes.com)

Hyperion Therapeutics Completes Initial Public Offering and Announces Exercise of Underwriters' OverOver----AllotmentAllotment OptOptionion

Hyperion Therapeutics, Inc. (South San Francisco, CA. USA) announced the completion of its initial public offering of 5,000,000 shares of common stock. In addition, the underwriters of its initial public offering exercised their over-allotment option in full and purchased an additional 750,000 shares of common stock. All of such shares were sold by Hyperion Therapeutics at the initial public offering price of USD 10.00 per share. Leerink Swann LLC and Cowen and Company, LLC acted as joint book-running managers for the proposed offering, and Needham & Company, LLC acted as co-manager of the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy. (Source: Company website)

JuLy 2012 Financing rounds Summary from Biotechgate Amount in Type of Financing Company Name Sector Ownership Country Million USD Round Stage Biotechnology - Therapeutics Debt Acusphere, Inc. 8 Public USA and Diagnostics financing Adamis Biotechnology - Therapeutics Series C / Equity - First 1 Public USA Pharmaceuticals and Diagnostics 3. Round stage Biotechnology - Therapeutics Equity - Later Private / Aerial BioPharma 3.8 USA and Diagnostics stage independent Biotechnology - Therapeutics Series C / Equity - Private / Agile Therapeutics 40 USA and Diagnostics 3. Round Second stage independent Biotechnology - Therapeutics Alimera Sciences 40 Other Other Public USA and Diagnostics Allegro Diagnostics Series A / Private / Biotechnology / R&D Services 5.4 n/a USA Corp. 1. Round independent Altor BioScience Biotechnology - Therapeutics Equity - Later Private / 11.3 USA Corporation and Diagnostics stage independent Apellis Biotechnology - Therapeutics Private / 0.7 n/a USA Pharmaceuticals and Diagnostics independent Armune BioScience, Biotechnology - Therapeutics Private / 1.1 n/a USA Inc. and Diagnostics independent Arrogene Biotechnology - Therapeutics Equity - Later Private / 3.7 USA Nanotechnology, Inc. and Diagnostics stage independent Series D / Private / Avinger Medical Technology 33 n/a USA 4. Round independent Biotechnology - Therapeutics Bionor Pharma ASA 1.7 n/a Public Norway and Diagnostics Biotechnology - Therapeutics Series D / Equity - Later Private / bluebird bio 60 USA and Diagnostics 4. Round stage independent Biotechnology - Therapeutics Equity - First Private / Callidus Biopharma 1.6 USA and Diagnostics stage independent Biotechnology - Therapeutics Private / Carmot Therapeutics 0.5 n/a USA and Diagnostics independent Series A / Equity - Private / CartiHeal Medical Technology 10 Israel 1. Round Start-up independent Biotechnology - Therapeutics Private / United Cell Medica Ltd 17 Other and Diagnostics independent Kingdom Biotechnology - Therapeutics Series D / Equity - Later Private / Chiasma 38.5 USA and Diagnostics 4. Round stage independent Biotechnology - Therapeutics Series D / Equity - Later Private / Chiasma (Israel) ltd. 38.5 Israel and Diagnostics 4. Round stage independent Coda Therapeutics, Biotechnology - Therapeutics Series B / Equity - Private / 19.4 USA Inc. and Diagnostics 2. Round Second stage independent Biotechnology - Therapeutics Series B / Equity - Private / Coferon, Incorporated 12 USA and Diagnostics 2. Round Start-up independent Private / Curefab GmbH Medical Technology n/a Other n/a Germany independent

Biotechnology - Therapeutics Series B / Equity - Private / CytomX Therapeutics 11 USA and Diagnostics 2. Round Second stage independent Biotechnology - Therapeutics Private / DOMAIN Therapeutics 2 n/a France and Diagnostics independent Durata Therapeutics, Biotechnology - Therapeutics 77.6 Other IPO Public USA Inc. and Diagnostics Epinex Diagnostics, Biotechnology - Therapeutics Private / 0.9 n/a USA Inc. and Diagnostics independent Series A / Private / Epivios Medical Technology n/a Equity - Seed Germany 1. Round independent Biotechnology - Therapeutics Series C / Equity - Private / GenKyoTex S.A. 26 Switzerland and Diagnostics 3. Round Second stage independent Histogenics Series A / Equity - Private / Medical Technology 49 USA Corporation 1. Round Start-up independent Biotechnology - Therapeutics Hyperion Therapeutics 57.5 Other IPO Public USA and Diagnostics Biotechnology - Therapeutics Series A / Equity - Private / Inbiomotion SL 2 Spain and Diagnostics 1. Round Start-up independent

IntegraGen SA Biotechnology / R&D Services 2.4 Other Other Public France

Biotechnology - Therapeutics Series B / Private / Juventas Therapeutics 22.2 n/a USA and Diagnostics 2. Round independent Biotechnology - Therapeutics Private / Knopp Biosciences LLC 30 Other Other USA and Diagnostics independent

MDxHealth S.A. Biotechnology / R&D Services 10 Other Post-IPO Public Belgium

Biotechnology - Therapeutics Medgenics, Inc. 9.5 Other Post-IPO Public USA and Diagnostics Mersana Therapeutics, Biotechnology - Therapeutics Series A / Equity - First Private / 27 USA Inc. and Diagnostics 1. Round stage independent Nabi Biotechnology - Therapeutics 23 Other Post-IPO Public USA Biopharmaceuticals and Diagnostics Biotechnology - Therapeutics Equity - First NantPharma 125 Subsidiary USA and Diagnostics stage Biotechnology - Therapeutics Equity - Later Private / Neos Therapeutics 18.3 USA and Diagnostics stage independent Series A / Private / Neuravi Limited Medical Technology 5.2 n/a Ireland 1. Round independent Biotechnology - Therapeutics Series B / Equity - First Private / NexDx. Inc. 2.1 USA and Diagnostics 2. Round stage independent Biotechnology - Therapeutics Novavax, Inc. 2 Other Other Public USA and Diagnostics Equity - Later Private / Nuevolution A/S Biotechnology / R&D Services 80.5 Denmark stage independent Biotechnology - Therapeutics Omeros Corporation 32.3 Post-IPO Public USA and Diagnostics Biotechnology - Therapeutics Private / Omniox 1 Other Other USA and Diagnostics independent

Onconova Biotechnology - Therapeutics Equity - Later Private / 26.4 USA Therapeutics, Inc. and Diagnostics stage independent

Oragenics Biotechnology - other 12.9 Other Post-IPO Public USA

Palatin Technologies, Biotechnology - Therapeutics Series A / 35 n/a Public USA Inc. and Diagnostics 1. Round Series B / Equity - Private / Pearltec AG Medical Technology 2 Switzerland 2. Round Start-up independent Biotechnology - Therapeutics Debt Private / PhaseRx, Inc. 1.6 USA and Diagnostics financing independent Biotechnology - Therapeutics Series A / Private / Phthisis Diagnostics 0.41 Equity - Seed USA and Diagnostics 1. Round independent PIQUR Therapeutics Biotechnology - Therapeutics Equity - First Private / 15 Switzerland Ltd. and Diagnostics stage independent Prexton Therapeutics Biotechnology - Therapeutics Series A / Private / 2.1 Equity - Seed Switzerland S.A and Diagnostics 1. Round independent Prosetta Biotechnology - Therapeutics Equity - First Private / 2 USA Bioconformatics Inc and Diagnostics stage independent PsiOxus Therapeutics Biotechnology - Therapeutics Series B / Equity - First Private / United 22 Ltd. and Diagnostics 2. Round stage independent Kingdom Biotechnology - Therapeutics Equity - Later Private / PTC Therapeutics, Inc. 30 USA and Diagnostics stage independent Biotechnology - Therapeutics Series A / Equity - Private / RDD Pharma Ltd. 7.2 Israel and Diagnostics 1. Round Start-up independent Relmada Therapeutics Biotechnology - Therapeutics Series A / Equity - First Private / 3 USA Inc. and Diagnostics 1. Round stage independent Remedy Biotechnology - Therapeutics Equity - Later Private / 4 USA Pharmaceuticals, Inc. and Diagnostics stage independent Biotechnology - Therapeutics Equity - Later Private / Revalesio 10 USA and Diagnostics stage independent Sprout Biotechnology - Therapeutics Series A / Private / 20 Equity - Seed USA Pharmaceuticals and Diagnostics 1. Round independent Biotechnology - Therapeutics Private / TesoRx Pharma 5.9 n/a USA and Diagnostics independent Tolero Biotechnology - Therapeutics Equity - Later Private / 3.3 USA Pharmaceuticals, Inc. and Diagnostics stage independent TrueVision 3D Surgical, Debt Private / Medical Technology 2.5 USA Inc. financing independent Ultragenyx Biotechnology - Therapeutics Series A / Equity - First Private / 15.1 USA Pharmaceutical Inc. and Diagnostics 1. Round stage independent Biotechnology - Therapeutics Private / Vaxart, Inc. 4.3 n/a USA and Diagnostics independent Biotechnology - Therapeutics Debt Private / ZS Pharma, Inc. 5.3 USA and Diagnostics financing independent

Therapeutic BIoTech Financing – Last 13 Months1

Financing Worldwide (in USD millions)

Biotechnology - Therapeutics and Diagnostics Private/independent Companies Grand Year 2011 2011 2011 2011 2011 2011 2012 2012 2012 2012 2012 2012 2012 Total Month Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul

Totals 300 196 336 434 669 254 326 274 571 398 275 320 593 4’944 US 205 150 202 379 466 172 177 219 502 308 239 285 436 3’741 Europe 41 27 106 55 200 70 138 24 69 32 24 28 111 925 Rest of World 54 19 28 0 3 11 11 31 0 58 13 6 46 279

Copyright © 2012 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebiotech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com

Source Biotechgate